Phase 1b/2/3 studies in RRMM after ≥2... | American Society of Hematology

Phase 1b/2/3 studies in RRMM after ≥2 prior lines of therapy that included lenalidomide- or double-refractory patients (subgroup analysis)

	CASTOR⁷ Dara-Bort-Dex (N = 251)	ENDEAVOR⁸ Carf-Dex (N = 464)	OPTIMISMM⁹ Pom-Bort-Dex (N = 281)	MMY1001^5,10 Dara-Pom-Dex (N = 103)	ELOQUENT-3⁶ Elo-Pom-Dex (N = 60)	MMY1001¹⁰ Dara-Carf-Dex (N = 85)
Study phase	3	3	3	1b	2	1b
Median prior lines of therapy (range)	2 (1-9)	2 (1-2)	2 (1-3)	4 (1-13)	3 (2-8)	2 (1-4)
Prior exposure to class/agent (%)
IMiD	71	70	100	100	100	100
Lenalidomide	36	38	100	100	90	95
PI	67	54	75	99	100	100
Bortezomib	65	54	72	98	100	100
IMiD + PI	45	34	75	99	100	100
Refractory to (%)
Lenalidomide	24	24	71	89	98	60
Bortezomib	—	3	9	71	100	31
Lenalidomide + bortezomib	—	NR	5	71	68	29
Last prior line of therapy	30	NR	70	NR	100	NR
Lenalidomide in last prior line of therapy	18	NR	23	NR	NR	NR
Overall response (%)	84	77	82	60	53	86
Lenalidomide-refractory	81	NR	NR	57.5*	NR	81
≥Very good partial response (%)	62	54	53	42	20	73
Median PFS, mo	16.7	18.7	11	8.8	10.3	Not reached (62% at 1 y)
Lenalidomide-refractory	9.3†	8.6	9.5 (17.8)‡	NR	NR	14.1

	CASTOR⁷ Dara-Bort-Dex (N = 251)	ENDEAVOR⁸ Carf-Dex (N = 464)	OPTIMISMM⁹ Pom-Bort-Dex (N = 281)	MMY1001^5,10 Dara-Pom-Dex (N = 103)	ELOQUENT-3⁶ Elo-Pom-Dex (N = 60)	MMY1001¹⁰ Dara-Carf-Dex (N = 85)
Study phase	3	3	3	1b	2	1b
Median prior lines of therapy (range)	2 (1-9)	2 (1-2)	2 (1-3)	4 (1-13)	3 (2-8)	2 (1-4)
Prior exposure to class/agent (%)
IMiD	71	70	100	100	100	100
Lenalidomide	36	38	100	100	90	95
PI	67	54	75	99	100	100
Bortezomib	65	54	72	98	100	100
IMiD + PI	45	34	75	99	100	100
Refractory to (%)
Lenalidomide	24	24	71	89	98	60
Bortezomib	—	3	9	71	100	31
Lenalidomide + bortezomib	—	NR	5	71	68	29
Last prior line of therapy	30	NR	70	NR	100	NR
Lenalidomide in last prior line of therapy	18	NR	23	NR	NR	NR
Overall response (%)	84	77	82	60	53	86
Lenalidomide-refractory	81	NR	NR	57.5*	NR	81
≥Very good partial response (%)	62	54	53	42	20	73
Median PFS, mo	16.7	18.7	11	8.8	10.3	Not reached (62% at 1 y)
Lenalidomide-refractory	9.3†	8.6	9.5 (17.8)‡	NR	NR	14.1

Bort, bortezomib; Carf, carfilzomib; Dara, daratumumab; Dex, dexamethasone; Elo, elotuzumab; NR, not reported; Pom, pomalidomide.

PI + IMiD refractory.

Refractory to lenalidomide in last prior line of therapy.

Refractory to lenalidomide in first-line of therapy.